Work

Characterization and impact of response to holding/bridging therapy in second-line large Bcell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry

Year: 2026
Type: article
Study design: Observational Study
Abstract: The optimal approach for holding or bridging therapy (H/BT) prior to second line axicabtagene ciloleucel (axi-cel) remains undefined, and the prognostic impact of response to H/BT remains debated. Here, we characterize real-world H/BT strategies and evaluate the impact of response on outcome following axi-cel infusion in the second-line setting for relapse or refractory (R/R) large B-cell lymphoma (LBCL). We included all adults with R/R LBCL within 12 months of first-line therapy who received axi-cel in the nationwide French DESCAR-T cohort (NCT04328298). The primary objective was to EFS between H/BT responders and nonresponders, as per Lugano criteria, using propensity score matching (PSM). Secondary objectives were to characterize H/BT modalities, corresponding responses, and to identify predictors of EFS at infusion. Among 566 patients included, 469 (83%) received chemotherapy-based H/BT, while 97 (17%) received a chemo-free approach, including no H/BT. Patients treated with chemotherapy-based H/BT had more advanced disease characteristics and exhibited inferior EFS compared to those receiving chemo-free approaches. After PSM, OS was significantly improved in responders versus non-responders (HR=0·70 [95% CI 0·51-0·96], p=0·0292), while the EFS benefit no longer reached statistical significance (HR=0·86 [95%CI 0·70-1·07], p=0·1739). Given that only patients ultimately receiving axi-cel were analyzed, the impact of H/BT response may have been underestimated. A predictive score combining response to H/BT, international prognostic index, LDH, and CRP at infusion identified two risk groups with significantly different EFS. In conclusion, H/BT response appears to be associated with axi-cel outcomes particularly when combined to inflammatory markers and residual LDH.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W7236828710
FWCI:
Cites: 23
Cited by:
Related to: 10